[Efficacy and tolerance of risperidone in various doses (report of a study)].

Q4 Medicine
Ceska a Slovenska Psychiatrie Pub Date : 1996-02-01
E Cesková, J Svestka
{"title":"[Efficacy and tolerance of risperidone in various doses (report of a study)].","authors":"E Cesková,&nbsp;J Svestka","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Risperidone was compared in 2 double blind studies with haloperidol and perphenazine in schizophrenic psychoses. According to the maximal daily dose achieved the risperidone group was divided in 4 subgroups and the risperidone efficacy and tolerability in these groups were compared both mutually and in relation to the baseline. With all doses a good global antipsychotic efficacy has been observed. There were no statistically significant differences in influencing of productive or negative symptoms with exception of significantly more pronounced reduction of productive catatonic symptoms with 2 < max < or = 5 mg in comparison with doses higher than 15 mg daily. Extrapyramidal symptoms were less frequent with lower doses: with 2 < max < or = 5 mg significantly lower occurrence of increased muscle tonus and tremor was found than with higher doses. With maximal daily doses above 10 mg antiparkinson drugs had to be applied in more patients and in the case of trihexyphenidyl this difference reached a statistically significant level.</p>","PeriodicalId":39713,"journal":{"name":"Ceska a Slovenska Psychiatrie","volume":"92 1","pages":"50-6"},"PeriodicalIF":0.0000,"publicationDate":"1996-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ceska a Slovenska Psychiatrie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Risperidone was compared in 2 double blind studies with haloperidol and perphenazine in schizophrenic psychoses. According to the maximal daily dose achieved the risperidone group was divided in 4 subgroups and the risperidone efficacy and tolerability in these groups were compared both mutually and in relation to the baseline. With all doses a good global antipsychotic efficacy has been observed. There were no statistically significant differences in influencing of productive or negative symptoms with exception of significantly more pronounced reduction of productive catatonic symptoms with 2 < max < or = 5 mg in comparison with doses higher than 15 mg daily. Extrapyramidal symptoms were less frequent with lower doses: with 2 < max < or = 5 mg significantly lower occurrence of increased muscle tonus and tremor was found than with higher doses. With maximal daily doses above 10 mg antiparkinson drugs had to be applied in more patients and in the case of trihexyphenidyl this difference reached a statistically significant level.

[不同剂量利培酮的疗效和耐受性(一项研究报告)]。
在两项双盲研究中,利培酮与氟哌啶醇和奋那嗪治疗精神分裂症。根据达到的最大日剂量将利培酮组分为4个亚组,相互比较各组利培酮的疗效和耐受性,并与基线进行比较。所有剂量均有良好的整体抗精神病疗效。在对生产性或阴性症状的影响方面,没有统计学上的显著差异,除了2 < max <或= 5mg与每日高于15mg的剂量相比,生产性紧张性症状的减轻更为显著。较低剂量时锥体外系症状较少:2 < max <或= 5mg时,肌肉张力增加和震颤的发生率明显低于较高剂量时。每日最大剂量超过10毫克的抗帕金森药物必须应用于更多的患者,在三苯基的情况下,这种差异达到了统计学上显著的水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ceska a Slovenska Psychiatrie
Ceska a Slovenska Psychiatrie Medicine-Psychiatry and Mental Health
CiteScore
0.40
自引率
0.00%
发文量
1
期刊介绍: Závislost na psychoaktivních látkách je komplexní, multifaktoriální onemocnění, které se vyvine ze souhry genetických predispozic a faktorů okolního prostředí. Vznik a vývoj závisl...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信